• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Amir T. Fathi, MD


  • Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, Fathi AT, Peterson RT, Kung AL, Sweetser DA, Yeh JR.AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.Blood. 2013 Jun 13;121(24):4906-16.
  • Sadrzadeh H, Kerr DA, Cin PD, Lindeman NI, Hasserjian RP, Fathi AT.A unique PML-RARα rearrangement involving chromosomes 11, 15, and 17 in a patient with acute promyelocytic leukemia.Exp Hematol. 2013 May 6.
  • Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT.Trends in all-cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology, and End Results database analysis.Cancer. 2013 Apr 26.
  • Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Scd DS, Fathi AT.Association between baseline body mass index (BMI) and overall survival among patients over age 60 with acute myeloid leukemia (AML).Am J Hematol. 2013 Apr 26.
  • Sadrzadeh H, Hasserjian R, Fathi AT.Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.Am J Hematol. 2013 Mar;88(3):240-1.
  • Sadrzadeh H, Huck AE, Chen YB, Hasserjian RP, Fathi AT.Philadelphia chromosome positive B-cell lymphoblastic lymphoma isolated to bone.Leuk Lymphoma. 2013 Jan 30.
  • Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP.Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.Mod Pathol. 2013 Jan 11.
  • Sadrzadeh H, Abtahi SM, Fathi AT.Infectious pathogens and hematologic malignancy.Discov Med. 2012 Dec;14(79):421-33.
  • Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB.Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.Blood. 2012 Oct 16.
  • Fathi AT, Preffer FI, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, McAfee SL, Dillon L, Chen YB, Hasserjian RP.CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis.Leuk Lymphoma. 2012 Sep 28.
  • Fathi AT, Chen YB, Carter BW, Ryan RJ.Case records of the Massachusetts General Hospital. Case 24-2012. A 38-year-old man with abdominal pain and altered mental status.N Engl J Med. 2012 Aug 9;367(6):552-63.
  • Fathi A, Levis M.FLT3 inhibitors: a story of the old and the new.Curr Opin Hematol. 2011 Mar;18(2):71-6.
  • Fathi AT, Grant S, Karp JE.Exploiting cellular pathways to develop new treatment strategies for AML.Cancer Treat Rev. 2010 Apr;36(2):142-50. Review.
  • Fathi AT, Karp JE.New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.Curr Oncol Rep. 2009 Sep;11(5):346-52. Review.